Erlizumab
Based on 1 Customer Validation
Erlizumab (rhuMAb) is a monoclonal antibody against the Integrin b2/ITGB2/CD18 subunit of the Mac-1 receptor. Erlizumab can reduce reperfusion injury in myocardial infarction.
For research use only. We do not sell to patients.
- Purity: 98.49%
- CAS No.: 211323-03-4
- Molecular Weight:49.293 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Fab-G1-kappa
Human
Integrin b2/ITGB2/CD18
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Fab-G1-kappa
ELISA, FACS, Functional assay
-
Immobilized Integrin alpha X beta 2 Protein, Human (HEK293, His, HY-P73863) can bind Erlizumab. The EC50 for this effect is 832.3 ng/mL.
Chemical Information
-
CAS No. 211323-03-4
-
Appearance Liquid
-
Molecular Weight 49.293 kDa
-
Color Colorless to light yellow
-
SMILES
[Erlizumab]
-
Synonyms
rhuMAb
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (255 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)